Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Broad-Spectrum Antiviral Therapeutics

Figure 4

DRACOs were effective against rhinovirus 1B in NHLF cells.

(A) 100 nM DRACO was effective against 130 pfu/well rhinovirus, whereas 100 nM negative controls were not (12 dpi). (B) Cell viability measured 7 dpi showed little difference if 100 nM DRACO-containing medium was removed 3 dpi when untreated cells had widespread CPE from 130 pfu/well rhinovirus 1B; there was no relapse of viral CPE in treated cells after DRACOs were withdrawn. (C) 1 dose of 25 nM PTD-PKR-Apaf DRACO was effective against rhinovirus 1B in NHLF cells when it was added from 6 days before infection to 3 days after infection. (Complete viral CPE in untreated cell populations required 3–4 days in our experiments, and for these experiments a significant fraction of cells were still uninfected 3 dpi.) Cell viability was measured 14 dpi.

Figure 4